We narrowed to 782 results for: promoter

#164510-AAV9

Ready-to-use AAV9 particles produced from pAAV.hSynap.(cyto)iGlucoSnFR-mRuby2 (#164510). In addition to the viral particles, you will also receive purified pAAV.hSynap.(cyto)iGlucoSnFR-mRuby2 plasmid DNA. Synapsin-driven, cytosolic-targeted iGlucoSnFR-mRuby2

Loren Looger

Keller et al Cell Rep. 2021 Jun 22;35(12):109284. doi

Nov. 29, 2021

Academic Institutions and Nonprofits only

#137125-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-sRGECO (#137125). In addition to the viral particles, you will also receive purified pAAV-Ef1a-sRGECO plasmid DNA. EF1a-driven expression of cytosolic sRGECO calcium sensor. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

May 6, 2021

Academic Institutions and Nonprofits only

#104495-AAVrg

Ready-to-use AAV Retrograde particles produced from pGP-AAV-CAG-FLEX-jGCaMP7s-WPRE (#104495). In addition to the viral particles, you will also receive purified pGP-AAV-CAG-FLEX-jGCaMP7s-WPRE plasmid DNA. CAG-driven, Cre-dependent GCaMP7s calcium sensor. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al Nat Methods. 2019 Jul;16(7):649-657. doi

Oct. 3, 2019

Academic Institutions and Nonprofits only

#106176-AAV1

Ready-to-use AAV1 particles produced from pAAV.hSynapsin.SF-iGluSnFR.S72A (#106176). In addition to the viral particles, you will also receive purified pAAV.hSynapsin.SF-iGluSnFR.S72A plasmid DNA. hSynapsin driven SF-iGluSnFR.S72A, glutamate sensor. The S72A mutant has lower affinity for glutamate. Slower on-rate and faster off-rate. Enhanced temporal resolution and spatial resolution. These AAV preparations are suitable purity for injection into animals.

Loren Looger

Marvin et al Nat Methods. 2018 Nov;15(11):936-939. do

Feb. 25, 2019

Academic Institutions and Nonprofits only

#100857-AAV1

Ready-to-use AAV1 particles produced from pAAV.Syn.NES-jRGECO1b.WPRE.SV40 (#100857). In addition to the viral particles, you will also receive purified pAAV.Syn.NES-jRGECO1b.WPRE.SV40 plasmid DNA. Syn-driven jRGECO1b calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al eLife. 2016 Mar 24;5. pii: e12727. doi:

May 18, 2018

Academic Institutions and Nonprofits only

#50457-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSyn-DIO-EGFP (#50457). In addition to the viral particles, you will also receive purified pAAV-hSyn-DIO-EGFP plasmid DNA. hSyn-driven, Cre-dependent EGFP expression. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Sept. 22, 2025

Academic Institutions and Nonprofits only

#105321-AAV1

Ready-to-use AAV1 particles produced from pGP-AAV-syn-jGCaMP7c variant 1513-WPRE (#105321). In addition to the viral particles, you will also receive purified pGP-AAV-syn-jGCaMP7c variant 1513-WPRE plasmid DNA. Synapsin-driven jGCaMP7c expression. jGCaMP7c exhibits high contrast between peak fluorescence and resting fluorescence. It is useful for activity imaging of large populations of densely-labeled neurons because background fluorescence from inactive neurons is reduced. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al Nat Methods. 2019 Jul;16(7):649-657. doi

July 12, 2019

Academic Institutions and Nonprofits only

#20949-AAV9

Ready-to-use AAV9 particles produced from pAAV-double floxed-eNpHR-EYFP-WPRE-pA (#20949). In addition to the viral particles, you will also receive purified pAAV-double floxed-eNpHR-EYFP-WPRE-pA plasmid DNA. EF1a-driven, cre-dependent eNpHR EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

July 12, 2018

Academic Institutions and Nonprofits only

#105677-AAV5

Ready-to-use AAV5 particles produced from pAAV_hSyn1-SIO-stGtACR2-FusionRed (#105677). In addition to the viral particles, you will also receive purified pAAV_hSyn1-SIO-stGtACR2-FusionRed plasmid DNA. Synapsin-driven, Cre-dependent, soma-targeted anion-conducting channelrhodopsin fused to FusionRed for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Mahn et al Nat Commun. 2018 Oct 8;9(1):4125. doi: 1

Oct. 21, 2024

Academic Institutions and Nonprofits only

#37825-CAP-B10

Ready-to-use AAV CAP-B10 particles produced from pAAV-CAG-GFP (#37825). In addition to the viral particles, you will also receive purified pAAV-CAG-GFP plasmid DNA. CAG-driven GFP expression. These AAV were produced with the CAP-B10 serotype, which permits efficient transduction of both inhibitory and excitatory neurons in the central nervous system. These AAV preparations are suitable purity for injection into animals.

Edward Boyden

Nov. 8, 2023

Academic Institutions and Nonprofits only

#178329-AAV1

Ready-to-use AAV1 particles produced from pAAV.hSyn.iGluSnFR3.v857.PDGFR (#178329). In addition to the viral particles, you will also receive purified pAAV.hSyn.iGluSnFR3.v857.PDGFR plasmid DNA. Synapsin-driven, third generation glutamate sensor iGluSnFR3, variant 857. These AAV preparations are suitable purity for injection into animals.

Kaspar Podgorski

Aggarwal et al Nat Methods. 2023 May 4. doi: 10.1038/s4

May 16, 2023

Academic Institutions and Nonprofits only

#117382-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hSyn1-eYFP (#117382). In addition to the viral particles, you will also receive purified pAAV-hSyn1-eYFP plasmid DNA. hSyn-driven eYFP expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Viviana Gradinaru

Challis et al Nat Protoc. 2019 Feb;14(2):379-414. doi:

Oct. 18, 2021

Academic Institutions and Nonprofits only

#123310-AAV9

Ready-to-use AAV9 particles produced from pAAV-hSyn-GRAB_NEmut (#123310). In addition to the viral particles, you will also receive purified pAAV-hSyn-GRAB_NEmut plasmid DNA. hSyn-driven expression of GRAB-NEmut control norepinephrine sensor (does not respond to NE). These AAV preparations are suitable purity for injection into animals.

Yulong Li

Feng et al Neuron. 2019 May 22;102(4):745-761.e8. d

March 12, 2021

Academic Institutions and Nonprofits only

#119744-AAV5

Ready-to-use AAV5 particles produced from AAV CAMKII PSAM4 GlyR IRES EGFP (#119744). In addition to the viral particles, you will also receive purified AAV CAMKII PSAM4 GlyR IRES EGFP plasmid DNA. CamKII-driven expression of PSAM4 GlyR IRES EGFP for neuronal silencing. These AAV preparations are suitable purity for injection into animals.

Scott Sternson

Magnus et al Science. 2019 Mar 14. pii: science.aav52

Aug. 28, 2020

Academic Institutions and Nonprofits only

#35505-AAV9

Ready-to-use AAV9 particles produced from pAAV-CaMKIIa-hChR2(E123A)-EYFP (#35505). In addition to the viral particles, you will also receive purified pAAV-CaMKIIa-hChR2(E123A)-EYFP plasmid DNA. CaMKIIa-driven hChR2(E123A)-EYFP expression for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Mattis et al Nat Methods. 2011 Dec 18;9(2):159-72. do

May 24, 2018

Academic Institutions and Nonprofits only

#234441-AAV1

Ready-to-use AAV1 particles produced from pAAV-syn-flex-iGluSnFR4s-NGR-WPRE (#234441). In addition to the viral particles, you will also receive purified pAAV-syn-flex-iGluSnFR4s-NGR-WPRE plasmid DNA. Syn-driven, iGluSnFR4s-NGR sensor expression. These AAV preparations are suitable purity for injection into animals.

GENIE Project

Aggarwal et al Nat Methods. 2026 Feb;23(2):417-425. doi

Sept. 22, 2025

Academic Institutions and Nonprofits only

#105530-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV.CMV.PI.EGFP.WPRE.bGH (#105530). In addition to the viral particles, you will also receive purified pAAV.CMV.PI.EGFP.WPRE.bGH plasmid DNA. CMV-driven EGFP control. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

Feb. 16, 2024

Academic Institutions and Nonprofits only

#55650-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-hSyn Con/Fon EYFP (#55650). In addition to the viral particles, you will also receive purified pAAV-hSyn Con/Fon EYFP plasmid DNA. Synapsin driven, Cre and Flp-dependent EYFP expression. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Sept. 8, 2020

Academic Institutions and Nonprofits only

#124650-AAV9

Ready-to-use AAV9 particles produced from pAAV-CamKIIa-C1V1(t/t)-mScarlet-KV2.1 (#124650). In addition to the viral particles, you will also receive purified pAAV-CamKIIa-C1V1(t/t)-mScarlet-KV2.1 plasmid DNA. CamKIIa-driven expression of C1V1(t/t) fused to mScarlet fluorophore and targeted to neuronal soma for optogenetic activation. These AAV preparations are suitable purity for injection into animals.

Christopher Harvey

Chettih et al Nature. 2019 Mar 6. pii: 10.1038/s41586-

Dec. 2, 2019

Academic Institutions and Nonprofits only

#121675-AAV1

Ready-to-use AAV1 particles produced from pAAV-EF1a-fDIO-Cre (#121675). In addition to the viral particles, you will also receive purified pAAV-EF1a-fDIO-Cre plasmid DNA. EF1a-driven, Flp recombinase dependent expression of Cre recombinase. These AAV preparations are suitable purity for injection into animals.

Esteban Engel, Alexander Nectow

Schneeberger et al Cell. 2019 Jun 24. pii: S0092-8674(19)30

Sept. 27, 2023

Academic Institutions and Nonprofits only